Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02484248 · ClinicalTrials.gov registry record · Phase 3
Ketotifen for Children With Functional Dyspepsia in Association With Duodenal Eosinophilia
A Phase 3 study of Functional Dyspepsia, sponsored by Craig A. Friesen, MD.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT02484248 is a Phase 3 study of Functional Dyspepsia that is actively recruiting participants, run by Craig A. Friesen, MD. The registered enrollment target is 40 participants, below the 68-participant average among 9 other Functional Dyspepsia trials with a reported enrollment target (41% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02484248, a Phase 3 study of Functional Dyspepsia, is actively recruiting participants, sponsored by Craig A. Friesen, MD.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
Acid reduction remains the most common treatment prescribed empirically by pediatric gastroenterologists for children with functional dyspepsia (FD). When acid reduction therapy fails to provide patients with a therapeutic effect, ketotifen and cromolyn, mast cell stabilizers, represent an attractive potential therapy given data implicating mast cells in the generation of dyspeptic symptoms. Although there have been no adult or pediatric studies on the use of mast cell stabilizers in patients with FD, benefit has been demonstrated in adults with IBS and children with eosinophilic gastroenteritis. Additionally, previous studies show mucosal eosinophilia is highly correlated with functional dyspepsia. Our usual current treatment pathway for functional dyspepsia in association with duodenal mucosal eosinophilia is as follows: acid-reducing medication/montelukast → addition of H1 antagonist → addition of budesonide → addition of oral cromolyn. If ketotifen is effective, it offers the advantage of being able to replace both the H1 antagonist and the oral cromolyn at a substantially reduced cost (approximately 10% of the cost of cromolyn alone). This study aims to introduce ketotifen earlier in the treatment pathway to examine its efficacy on children with functional dyspepsia in association with duodenal eosinophilia.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ketotifen
Study Locations (1)
Missouri
- The Children's Mercy Hospital - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2015-08 |
| Est. Completion | 2027-04-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02484248
The ClinicalTrials.gov registry entry for NCT02484248 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 68-participant average among 9 other Functional Dyspepsia trials with a reported enrollment target (41% lower). The listed sponsor is Craig A. Friesen, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Functional Dyspepsia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02484248 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT02484248 about?
NCT02484248 is a clinical study titled "Ketotifen for Children With Functional Dyspepsia in Association With Duodenal Eosinophilia". Acid reduction remains the most common treatment prescribed empirically by pediatric gastroenterologists for children with functional dyspepsia (FD). When acid reduction therapy fails to provide patients with a therapeutic effect, ketotifen and cromolyn, mast cell stabilizers, represent an attractiv...
What is the current status of trial NCT02484248?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2015-08. Estimated completion is 2027-04-01.
What conditions does trial NCT02484248 study?
This clinical trial studies the following conditions: Functional Dyspepsia.
What interventions are being tested in trial NCT02484248?
The interventions under investigation include: Placebo (DRUG), Ketotifen (DRUG).
Who is sponsoring clinical trial NCT02484248?
This trial is sponsored by Craig A. Friesen, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02484248 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Functional Dyspepsia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Synergistic Gut-brain Axis Modulation Via Vagal Stimulation and Support Therapy in Functional Dyspepsia
RECRUITING · NA
-
Exposure-Based CBT for Avoidant/Restrictive Food Intake in Functional Dyspepsia
RECRUITING · NA
-
Autonomic Reactivity and Personalized Neurostimulation
RECRUITING · NA
-
Functional Dyspepsia Treatment Using Virtual Reality
RECRUITING · NA
-
Brain-Gut Yoga for Functional Dyspepsia and Gastroparesis (FD-GP)
RECRUITING · NA
-
Cerebral Cortical Influences on Autonomic Function
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.